

## Special Issue

# New Advances in Haemostasis, Thrombosis and Angiology

### Message from the Guest Editor

Venous thromboembolism remains a leading cause of morbidity and mortality worldwide and a crucial global health concern. In recent decades, scientific advances in the understanding of the pathophysiology of hemostasis and thrombosis, as well as the introduction of new pharmacological agents for the prevention and treatment of venous thromboembolism, have revolutionized the biomedical and clinical landscape. In the near future, individualized approaches to venous thromboembolism risk stratification, prophylaxis, and treatment will allow us to significantly improve patient care.

The aim of this Special Issue is to provide an overview of exciting new research in the areas of hemostasis, thrombosis, and angiology, paving the way for personalized approaches to the management of venous thromboembolism.

We are soliciting basic, original, translational, and clinical papers, especially focusing on diagnostic and prognostic biomarkers as well as novel drug targets or targeted treatments, including clinical trials.

---

### Guest Editor

Dr. Corinne Frere

INSERM UMRS-1166, Institute of Cardiometabolism and Nutrition, GRC 27 GRECO, Sorbonne Université, F-75013 Paris, France

---

### Deadline for manuscript submissions

closed (10 August 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/92405](https://mdpi.com/si/92405)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).